Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
A phase 1/2 trial of PF-08634404 and Enfortumab vedotin in bladder & urothelial cancer, run by Pfizer, now recruiting.
Overview
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer is a phase 1/2 interventional study registered as NCT07421700 by Pfizer, with 132 participants planned, started 2026-03-11 and due to reach its primary completion in 2027-12-06. Interventions recorded: PF-08634404 and Enfortumab Vedotin.
Similar pages
not linked directly; found by shared links- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Astellas, Enfortumab vedotin, Pfizer (incl. Seagen), Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Shares Astellas, Enfortumab vedotin, Pfizer (incl. Seagen) and the tag pipeline.
- TrialEnfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Shares Astellas, Enfortumab vedotin, Pfizer (incl. Seagen), Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Shares Astellas, Enfortumab vedotin and the tag pipeline.
- TrialStudy of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Shares Astellas, Pfizer (incl. Seagen) and the tag pipeline.
- TrialA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Shares Enfortumab vedotin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Shares Enfortumab vedotin, Bladder & urothelial cancer and the tag pipeline.
- TrialTreatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Shares Enfortumab vedotin, Bladder & urothelial cancer and the tag pipeline.